Inventor
LEPPLA STEPHEN H
US29 patents
⚠️ This page may combine multiple inventors who share the name “LEPPLA STEPHEN H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
18 patentsUS5677274AOct 14, 1997
Anthrax toxin fusion proteins and related methods
US HEALTH119 citations95
US6592872B1Jul 15, 2003
Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US HEALTH62 citations94
US5591631AJan 7, 1997
Anthrax toxin fusion proteins, nucleic acid encoding same
US HEALTH77 citations93
US7261900B2Aug 28, 2007
Recombinant modified Bacillus anthracis protective antigen for use in vaccines
US HEALTH15 citations91
US7097965B2Aug 29, 2006
Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US HEALTH11 citations82
US9580492B2Feb 28, 2017
Monoclonal antibodies that neutralize anthrax toxins
US HEALTH2 citations72
US7947289B2May 24, 2011
Multimeric protein toxins to target cells having multiple identifying characteristics
US HEALTH6 citations69
US8961975B2Feb 24, 2015
Monoclonal antibodies that neutralize anthrax toxins
US HEALTH1 citations61
US8044189B2Oct 25, 2011
Bacillus anthracis protective antigen nucleic acid sequences
US HEALTH1 citations61
US7763451B2Jul 27, 2010
Methods for preparing Bacillus anthracis protective antigen for use in vaccines
US HEALTH2 citations58
US7468352B1Dec 23, 2008
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
US HEALTH3 citations56
US10227395B2Mar 12, 2019
Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin
US HEALTH0 citations51
US10053503B2Aug 21, 2018
Monoclonal antibodies that neutralize anthrax toxins
US HEALTH0 citations51
US8926986B2Jan 6, 2015
Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax
US HEALTH0 citations51
US7625736B2Dec 1, 2009
Methods for preparing immunogenic conjugates
US HEALTH0 citations50
US10273548B2Apr 30, 2019
Protease-deficient bacillus anthracis
US HEALTH0 citations46
US10835593B2Nov 17, 2020
Modified anthrax toxin protective antigen
US HEALTH0 citations43
US9890369B2Feb 13, 2018
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
US HEALTH0 citations42
LEPPLA STEPHEN H
3 patentsUS8703150B2Apr 22, 2014
Methods of using Bacillus anthracis protective antigen sequences for vaccination
LEPPLA STEPHEN H1 citations61
US8394387B1Mar 12, 2013
Recombinant modified Bacillus anthracis protective antigen for use in vaccines
LEPPLA STEPHEN H2 citations57
US8388933B2Mar 5, 2013
Multimeric protein toxins to target cells having multiple identifying characteristics
LEPPLA STEPHEN H3 citations57
THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES
2 patentsUS9730993B2Aug 15, 2017
Engineered anthrax lethal toxin for targeted delivery
THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES2 citations60
US9403872B2Aug 2, 2016
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES0 citations45